BioVaxys Announces New Closing Date for Private Placement Funding Opportunity

BioVaxys Extends Private Placement Closing Date

BioVaxys Technology Corp., a clinical-stage biopharmaceutical company based in British Columbia, Canada, has announced an extension of the closing date for its previously declared non-brokered private placement offering. The private placement was originally announced in January with a per-unit price set at $0.05. This offering includes one common share of the company and one share purchase warrant, which can be converted into an additional share at an exercise price of $0.15 over the next 24 months.

The new deadline for the closing of the fourth and final tranche of the private placement is now set for on or about February 14, 2025. This adjustment aims to provide potential investors with extra time to engage in the offering, thus broadening the pool of contributors. The company indicated that it will channel the net proceeds from this last tranche towards working capital, essential for supporting its ongoing and future projects.

Additionally, all securities expected to be issued as part of this tranche will be subjected to a statutory hold period of four months and one day, ensuring they comply with relevant securities laws.

A reminder for investors: this announcement does not constitute any solicitation to buy or sell securities in the United States, as the shares related to this offering have yet to be registered in accordance with the U.S. Securities Act of 1933 or corresponding state laws. They can only be offered or sold within the United States when they meet these registration requirements or fall under available exemptions.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. is committed to enhancing patient care by developing innovative immunotherapy solutions. Utilizing its proprietary DPX™ immune-educating technology platform and the HapTenix© neoantigen tumor cell construct, BioVaxys is focused on tackling challenges in the realms of oncology, infectious diseases, and immunological disorders. The DPX™ platform is known for its capability to facilitate targeted and lasting immune responses, promoting the delivery of bioactive molecules to regional lymph nodes.

The firm's advancements have been primarily documented through positive results in both preclinical and clinical studies. BioVaxys shares are actively traded on the Canadian Securities Exchange under the symbol BIOV and on the Frankfurt Stock Exchange, furthering opportunities for investment and partnership.

For more insights about their journey and technology, visit www.biovaxys.com and connect with them on social media platforms such as X and LinkedIn.

Conclusion

As BioVaxys continues to push forward with its ambitious plans to improve healthcare through immunotherapy, the extension of the private placement closing date for investors serves to emphasize its commitment to building strong financial foundations. The collaboration with investors can potentially catalyze further breakthroughs in innovative therapies that can improve and prolong patient lives.